Pharmaceutical initiatives to combat atherosclerosis—What to do with the good, the bad, and the ugly lipoproteins

LaRosa, 1999, Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials, JAMA,, 282, 2340, 10.1001/jama.282.24.2340 Marchioli, 1996, Meta-analysis, clinical trials, and transferability of research results into practice: The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease, Arch Intern Med, 156, 1158, 10.1001/archinte.1996.00440100050007 Ford, 1985, The role of plasma lipids in carotid bifurcation atherosclerosis, Ann Neurol, 17, 301, 10.1002/ana.410170314 van Merode, 1985, Serum HDL/total cholesterol ratio and blood pressure in asymptomatic atherosclerotic lesions of the cervical carotid arteries in men, Stroke, 16, 34, 10.1161/01.STR.16.1.34 Wilson, 1997, Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis, N Engl J Med, 337, 516, 10.1056/NEJM199708213370802 2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Gordon, 1977, High density lipoprotein as a protective factor against coronary artery disease, The Framingham Study. Am J Med, 62, 707 Stampfer, 1996, A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction, JAMA, 276, 882, 10.1001/jama.1996.03540110036029 Miller, 1996, Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project, Circulation, 94, 2146, 10.1161/01.CIR.94.9.2146 Cantin, 1998, Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study, J Am Coll Cardiol, 31, 519, 10.1016/S0735-1097(97)00528-7 Cobbaert, 1997, Modulation of Lp(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol, J Am Coll Cardiol, 30, 1491, 10.1016/S0735-1097(97)00353-7 Cheng, 2001, Lipoprotein (a) level and mortality in patients with critical lower limb ischaemia, Eur J Vasc Endovasc Surg, 22, 124, 10.1053/ejvs.2001.1431 Ballantyne, 2000, Hyperlipidemia: Diagnostic and therapeutic perspectives, J Clin Endocrinol Metab, 85, 2089, 10.1210/jc.85.6.2089 Avins, 2000, Do triglycerides provide meaningful information about heart disease risk?, Arch Intern Med, 160, 1937, 10.1001/archinte.160.13.1937 Rosenson, 1993, Myocardial injury the acute phase response and lipoprotein metabolism, J Am Coll Cardiol, 22, 933, 10.1016/0735-1097(93)90213-K Blake, 2001, Novel clinical markers of vascular wall inflammation, Circ Res, 89, 763, 10.1161/hh2101.099270 Mauriello, 2000, Hyperfibrinogenemia is associated with specific histocytological composition and complications of atherosclerotic carotid plaques in patients affected by transient ischemic attacks, Circulation, 101, 744, 10.1161/01.CIR.101.7.744 Freedman, 1995, Relation of serum uric acid to mortality and ischemic heart disease, The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol, 141, 637 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 335, 1001 Manninen, 1992, Implications for treatment, Circulation, 85, 37, 10.1161/01.CIR.85.1.37 Muldoon, 2001, Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials, BMJ, 322, 11, 10.1136/bmj.322.7277.11 Hebert, 1997, Cholesterol lowering with statin drugs, risk of stroke, and total mortality, An overview of randomized trials. JAMA, 278, 313 Bucher, 1998, Effect of HMGCoA reductase inhibitors on stroke, A meta-analysis of randomized controlled trials. Ann Intern Med, 128, 89 Byington, 2001, Reduction in stroke events with pravastatin, The Prospective Pravastatin Pooling (PPP) project. Circulation, 103, 387 Crouse, 1997, Reductase inhibitor monotherapy and stroke prevention, Arch Intern Med, 157, 1305, 10.1001/archinte.1997.00440330039004 Thompson, 1995, Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease, Curr Opin Lipidol, 6, 386, 10.1097/00041433-199512000-00010 Rosenson, 1998, Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction, JAMA, 279, 1643, 10.1001/jama.279.20.1643 Jukema, 1995, Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels, The Regression Growth Evaluation Statin Study (REGRESS). Circulation, 91, 2528 1995, Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S), Lancet, 345, 1274, 10.1016/S0140-6736(95)90926-5 1998, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS), Circulation, 97, 1440, 10.1161/01.CIR.97.15.1440 Furberg, 1994, Pravastatin, lipids, and major coronary events, Am J Cardiol, 73, 1133, 10.1016/0002-9149(94)90297-6 Miettinen, 1997, Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S), Circulation, 96, 4211, 10.1161/01.CIR.96.12.4211 Blake, 2000, Are statins anti-inflammatory?, Curr Control Trials Cardiovasc Med, 1, 161, 10.1186/CVM-1-3-161 Rosenson, 1996, Beyond low-density lipoprotein cholesterol: A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess, Arch Intern Med, 156, 1278, 10.1001/archinte.1996.00440110036006 Harper, 1999, New perspectives on the management of low levels of high-density lipoprotein cholesterol, Arch Intern Med, 159, 1049, 10.1001/archinte.159.10.1049 Hebert, 1997, Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials, JAMA, 278, 313, 10.1001/jama.1997.03550040069040 Eastern Stroke and Coronary Heart Disease Collaborative Research Group, 1998, Blood pressure, cholesterol, and stroke in eastern Asia, Lancet, 352, 1801, 10.1016/S0140-6736(98)03454-0 Sacco, 2001, High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study, JAMA, 285, 2729, 10.1001/jama.285.21.2729 Butowski, 1998, Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolemia: Data from the UK Lipid Clinics Programme, Eur Heart J, 19, 1328, 10.1053/euhj.1998.1044 Andrade, 1995, Discontinuation of antihyperlipidemic drugs, Do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med, 332, 1125 Pedersen, 1996, Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study, Arch Intern Med, 156, 2085, 10.1001/archinte.1996.00440170097011 Larsen, 1994, Drug treatment of dyslipoproteinemia, Med Clin North Am, 78, 225, 10.1016/S0025-7125(16)30184-5 Levy, 1993, A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin, Circulation, 87, III45 Illingworth, 1994, Comparative effects of lovastatin and niacin in primary hypercholesterolemia, A prospective trial. Arch Intern Med, 154, 1586, 10.1001/archinte.1994.00420140051007 Sprecher, 1994, Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients, Ann Intern Med, 120, 537, 10.7326/0003-4819-120-7-199404010-00002 Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am J Cardiol, 81, 582, 10.1016/S0002-9149(97)00965-X Brown, 1998, Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin, J Am Coll Cardiol, 32, 665, 10.1016/S0735-1097(98)00300-3 Pan, 1990, Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia, Clin Pharmacol Ther, 48, 201, 10.1038/clpt.1990.136 Sprecher, 1994, Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients, Ann Intem Med, 120, 537, 10.7326/0003-4819-120-7-199404010-00002 Istvan, 2001, Structural mechanism for statin inhibition of HMG-CoA reductase, Science, 292, 1160, 10.1126/science.1059344 Ness, 1996, Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation, Arch Biochem Biophys, 325, 242, 10.1006/abbi.1996.0030 Conde, 1996, Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig, J Lipid Res, 37, 2372, 10.1016/S0022-2275(20)37486-1 Ness, 1998, Atorvastatin action involves diminished recovery of hepatic HMG CoA reductase activity, J Lipid Res, 39, 75, 10.1016/S0022-2275(20)34205-X Marz, 2001, Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype, Circulation, 103, 1942, 10.1161/01.CIR.103.15.1942 Kastelein, 2000, Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels, Am J Cardiol, 86, 221, 10.1016/S0002-9149(00)00942-5 Bakker-Arkema, 1996, Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia, JAMA, 276, 128, 10.1001/jama.1996.03530260042029 Dart, 1997, A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia, Am J Cardiol, 80, 39, 10.1016/S0002-9149(97)00280-4 Halstenson, 1992, Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment, J Clin Pharmacol, 32, 124, 10.1002/j.1552-4604.1992.tb03816.x Grundy, 1988, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N Engl J Med, 319, 24, 10.1056/NEJM198807073190105 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, 1615 Weismantel, 2001, What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterollowering agents?, J Fam Pract, 50, 927 Mevacor (Lovastatin, MSD): United States Food and Drug Administration package insert. Merck, Sharp and Dohme, West Point, PA Zocor (Simvastatin, MSD). United States Food and Drug Administration package insert. Merck, Sharp and Dohme, West Point, PA Pravachol(Pravastatin sodium). United States Food and Drug Administration package insert. Bristol Meyers Squibb, Princeton, NJ Lescol (Fluvastatin sodium). Sandoz Pharmaceuticals Corporation, Product Circular, East Hanover, NJ Davignon, 1994, Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia, Am J Cardiol, 73, 339, 10.1016/0002-9149(94)90005-1 Yoshimura, 1992, The effects of pravastatin on hyperlipidemia in renal transplant recipients, Transplantation, 53, 94, 10.1097/00007890-199201000-00018 Kobashigawa, 1995, Effect of pravastatin on outcomes after cardiac transplantation, N Engl J Med, 333, 621, 10.1056/NEJM199509073331003 Schrama, 1998, Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients, Transplantation, 66, 1175, 10.1097/00007890-199811150-00011 Glueck, 1992, Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias, Am J Cardiol, 70, 1, 10.1016/0002-9149(92)91380-M Rosenson, 1993, Gemfibrozil-lovastatin associated myalgia, Am J Cardiol, 71, 497, 10.1016/0002-9149(93)90481-Q Pierce, 1990, Myopathy and rhabdomyolysis with lovastatin-gemfibrozil combination therapy, JAMA, 264, 71, 10.1001/jama.1990.03450010075034 Wiklund, 1993, Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia, Am J Med, 94, 13, 10.1016/0002-9343(93)90114-5 Rosenson, 1994, Safety of combined pravastatin-gemfibrozil therapy, Am J Cardiol, 74, 499, 10.1016/0002-9149(94)90913-X Athyros, 1997, Safety and efficacy of long-term statin-fibrate combination in patients with refractory familial combined hyperlipidemia, Am J Cardiol, 80, 608, 10.1016/S0002-9149(97)00430-X Weismantel, 2001, What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterollowering agents?, J Fam Pract, 50, 927 Newman, 1996, Carcinogenicity of lipid-lowering drugs, JAMA, 275, 55, 10.1001/jama.1996.03530250059028 Bjerre, 2001, Do statins cause cancer? A meta-analysis of large randomized clinical trials, Am J Med, 110, 716, 10.1016/S0002-9343(01)00705-7 Freeman, 2001, Pravastatin and the development of diabetes mellitus, Evidence of a protective treatment effect in the West of Scotland Coronary Prevention study. Circulation, 103, 357 Edwards, 2001, Statins and bone: Myth or reality?, Calcif Tissue Int, 69, 63, 10.1007/s00223-001-2017-7 Sposito, 1999, Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril), Am J Cardiol, 83, 1497, 10.1016/S0002-9149(99)00132-0 Scott, 2001, Statins for the prevention of Alzheimer's disease, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD003160 1984, WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up, Report of the Committee of Principal Investigators. Lancet, 2, 600 Staels, 1998, Mechanism of action of fibrates on lipid and lipoprotein metabolism, Circulation, 98, 2088, 10.1161/01.CIR.98.19.2088 Vu-Dac, 1995, Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor, J Clin Invest, 96, 741, 10.1172/JCI118118 Berthou, 1996, Opposite regulation of human versus mouse apoprotein A-I by fibrates in human apolipoprotein-A-I transgenic mice, J Clin Invest, 97, 2408, 10.1172/JCI118687 Jin, 1996, Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2), Arterioscler Thromb Vasc Biol, 16, 1052, 10.1161/01.ATV.16.8.1052 Jones, 1996, Effect of gemfibrozil on levels of lipoprotein(a) in type II hyperlipoproteinemia subjects, J Lipid Res, 37, 1298, 10.1016/S0022-2275(20)39159-8 Nordt, 1997, Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type I induced by insulin and its precursors, Circulation, 95, 677, 10.1161/01.CIR.95.3.677 Westphal, 2001, Effects of fenofibrate and gemfibrozil on plasma homocysteine, Lancet, 358, 39, 10.1016/S0140-6736(00)05271-5 Dierkes, 1999, Serum homocystene increases after therapy with fenofibrate or bezafibrate, Lancet, 354, 219, 10.1016/S0140-6736(99)02153-4 Frick, 1987, Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia, Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 317, 1237 Magarian, 1991, Gemfibrozil-induced myopathy, Arch Intern Med, 151, 1873, 10.1001/archinte.1991.00400090143027 Pierce, 1990, Myopathy and rhabdomyolysis with lovastatin-gemfibrozil combination therapy, JAMA, 264, 71, 10.1001/jama.1990.03450010075034 Athyros, 1997, Safety and efficacy of long-term statin-fibrate combination in patients with refractory familial combined hyperlipidemia, Am J Cardiol, 80, 608, 10.1016/S0002-9149(97)00430-X Miller, 1998, Clinical pharmacokinetics of fibric acid derivatives (fibrates), Clin Pharmacokinet, 34, 155, 10.2165/00003088-199834020-00003 Grundy, 1981, Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man, J Lipid Res, 22, 24, 10.1016/S0022-2275(20)34737-4 Illingworth, 1994, Comparative effects of lovastatin and niacin in primary hypercholesterolemia, A prospective trial. Arch Intern Med, 154, 1586, 10.1001/archinte.1994.00420140051007 Philipp, 1998, Effect of Niacin supplementation on fibrinogen levels in patients with peripheral vascular disease, Am J Cardiol, 82, 697, 10.1016/S0002-9149(98)00393-2 Probstfield, 1994, Nicotinic acid as a lipoprotein-altering agent, Therapy directed by the primary physician. Arch Intern Med, 154, 1557 Guyton, 1998, Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia, Am J Cardiol, 82, 737, 10.1016/S0002-9149(98)00448-2 Etchason, 1991, Niacininduced hepatitis: A potential side effect with low-dose timerelease niacin, Mayo Clin Proc, 66, 23, 10.1016/S0025-6196(12)61171-9 Garg, 1990, Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus, JAMA, 264, 723, 10.1001/jama.1990.03450060069031 Pasternak, 1991, Unstable myocardial ischemia after the initiation of niacin therapy, Am J Cardiol, 67, 904, 10.1016/0002-9149(91)90631-T Garg, 1999, Niacin treatment increases plasma homocyst(e)ine levels, Am Heart J, 138, 1082, 10.1016/S0002-8703(99)70073-6 Shepherd, 1979, The effects of cholestyramine on high density lipoprotein metabolism, Atherosclerosis, 33, 433, 10.1016/0021-9150(79)90036-4 Davidson, 1999, Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects, Arch Intern Med, 159, 1893, 10.1001/archinte.159.16.1893 Insult, 2001, Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial, Mayo Clin Proc, 76, 971, 10.4065/76.10.971 Spence, 1995, Combination therapy with colestipol and psyllium mucilloid in patients with hyperlipidemia, Ann Intern Med, 123, 493, 10.7326/0003-4819-123-7-199510010-00003